NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-03 14:39இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Shivalik Rasayan Files USFDA DMF for Avapritinib API (Brand Ayvakit: $700M 2025 Revenue)
Shivalik Rasayan has successfully filed a Drug Master File (DMF) with the USFDA for Avapritinib API, completing the Complete Assessment (CA). Avapritinib is used to treat Gastrointestinal Stromal Tumors (GIST) and is marketed under the brand name 'Ayvakit' by Sanofi, which generated $700 million in revenue during 2025. This milestone supports Shivalik's strategy of commercializing high-value oncology APIs for regulated global markets. For a company with TTM revenues of ₹375 crore, entering supply chains for multi-hundred-million-dollar innovator molecules represents a key growth driver.
உச்சம் நம்பிக்கை
என்ன மாறியதுShivalik Rasayan submitted its USFDA DMF for Avapritinib API and received Complete Assessment status.
ஏன் இது முக்கியம்Enables potential commercial supply of the API to pharmaceutical partners targeting the US market for a molecule with a $700 million global revenue base.
Brand 2025 Revenue (USD): 700 million USDFiling Date: 03.11.2026TTM Revenue (Company): ₹375 கோடி
📅 குறுகிய காலம்Positive sentiment for the stock as it validates the company's oncology pipeline execution, though immediate quarterly financial impact will depend on client tie-ups.
📈 நீண்ட காலம்Enhances long-term growth prospects for the API division by expanding high-margin oncology exports into regulated markets like the US.
⚠ அபாய எச்சரிக்கைகள்
Commercialization timeline dependent on ANDA/formulation partners and regulatory approvals
Revenue generation contingent on maintaining strict USFDA compliance at manufacturing sites
👀 கவனிக்க வேண்டியவை
Track subsequent customer qualification milestones, commercial supply contracts, and USFDA facility compliance at Dahej Unit-I.
Shivalik Rasayan Allots Shares & Warrants to Raise ₹30.75 Cr at ₹250/Share
Shivalik Rasayan's board approved the allotment of 2,82,000 equity shares at ₹250 per share (₹7.05 crore) to public investors and 9,47,990 fully convertible warrants at ₹250 per warrant (₹23.70 crore) to promoters and public entities. The combined preferential issue totals ₹30.75 crore, which represents roughly 3.8% of the company's ₹819 crore market capitalization. Promoter entity Growel Remedies received 4,28,000 warrants, while the rest went to public investors. Upon full dilution and conversion of warrants, paid-up equity share capital will increase to ₹8.49 crore across 1,69,80,355 equity shares.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe board formally allotted 2.82 lakh equity shares and 9.48 lakh convertible warrants on a preferential basis, expanding immediate and diluted share capital.
ஏன் இது முக்கியம்Provides ₹30.75 crore in equity funding to bolster the balance sheet and support operations, though it introduces an equity dilution of ~7.8% relative to the prior base.
Total fundraise value: Rs. 30,74,97,500Issue price per share/warrant: Rs. 250Fundraise vs Market Cap: ~3.8%Fully diluted shares: 1,69,80,355
📅 குறுகிய காலம்Neutral to slightly muted due to equity dilution and the issue price being at a discount to the current market price of ₹362.1.
📈 நீண்ட காலம்Strengthens capital reserves for working capital and API project commercialization, supporting the company's low-debt profile.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~7.8% on a fully diluted basis
Pricing discount compared to prevailing market prices
👀 கவனிக்க வேண்டியவை
Track the deployment timeline of the raised funds toward the Dahej expansion/API filings and monitor the exercise of warrants within the statutory 18-month window.
Shivalik Rasayan Limited announced the voting results of its Extra-Ordinary General Meeting held on August 20, 2026. Shareholders approved two special resolutions with over 99.99% majority. Resolution 1 approved the issuance of up to 3,72,000 equity shares to public investors on a preferential basis, while Resolution 2 approved the issuance of up to 9,48,000 fully convertible warrants to both promoter and public categories. In aggregate, these proposals represent up to 13.20 lakh shares, or approximately 8.38% of current outstanding equity capital.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders officially passed special resolutions approving preferential allotments of equity shares and convertible warrants.
ஏன் இது முக்கியம்The fundraise provides capital for ongoing growth initiatives (such as capacity integration and API filings), while introducing an 8.38% potential equity dilution.
📅 குறுகிய காலம்Formalizes shareholder backing for the preferential issue, clearing the regulatory path for board allotment.
📈 நீண்ட காலம்Capital raised via equity and warrant conversion will strengthen the balance sheet to fund ongoing validation and export initiatives.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~8.38% upon full warrant conversion
Pricing terms and end-use details not specified in this voting extract
👀 கவனிக்க வேண்டியவை
Track subsequent disclosures on issue price, total capital raised, allotment confirmation, and deployment of proceeds toward API or agrochemical business expansion.
Shivalik Rasayan Q1 Cons PAT Rises 59.5% YoY to ₹4.50 Cr; Final Dividend of ₹0.50
Shivalik Rasayan reported consolidated net sales of ₹96.34 cr for Q1 FY27 (quarter ended June 30, 2026), marking a 7.87% YoY increase from ₹89.31 cr in Q1 FY26, though down 6.30% sequentially from ₹102.82 cr. Consolidated net profit grew 59.54% YoY to ₹4.50 cr compared to ₹2.82 cr in the corresponding quarter last year, while declining from ₹7.17 cr in Q4 FY26. Basic EPS stood at ₹2.16 versus ₹1.02 in Q1 FY26. Additionally, the Board recommended a final dividend of ₹0.50 (10%) per equity share of face value ₹5 for FY26, subject to shareholder approval at the AGM on September 28, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுReported Q1 FY27 financial performance showing robust YoY bottom-line growth and fixed AGM/dividend dates.
ஏன் இது முக்கியம்Demonstrates margin resilience driven by Agrochemicals and Pharma Formulations despite persistent operating drag in the standalone API business.
Consolidated Net Sales: ₹96.34 கோடிConsolidated PAT: ₹4.50 கோடிYoY PAT Growth: +59.54%Dividend per share: ₹0.50Q1 வருவாய் vs TTM வருவாய்: ~26.2%
📅 குறுகிய காலம்Earnings show operational stability on a YoY basis; stock may see positive sentiment on margin expansion despite sequential softness.
📈 நீண்ட காலம்Growth hinges on commercialization of the 20 validated API molecules and capacity utilization at the expanded Dahej facilities.
⚠ அபாய எச்சரிக்கைகள்
Persistent operating losses in the API business segment (-₹1.98 cr in Q1).
Sequential revenue and profit contraction compared to Q4 FY26.
👀 கவனிக்க வேண்டியவை
Track turnaround and commercial ramp-up in the API segment which continues to report operating losses, alongside export filings traction from oncology validations.
Shivalik Rasayan to Raise Rs 9.30 Cr via Preferential Issue; EGM Scheduled for Aug 20
Shivalik Rasayan Limited has convened an Extraordinary General Meeting (EGM) on August 20, 2026, to seek shareholder approval for a preferential issue of 3,72,000 equity shares at Rs 250 per share, totaling Rs 9.30 crore. The company also proposes issuing 9,48,000 fully convertible warrants to both Promoter and Public categories. The equity issue price of Rs 250 represents a slight discount to the current market price of Rs 259.9. Notably, Non-Executive Director Ashwani Kumar Sharma is a proposed allottee for 1,32,000 shares.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is initiating a small-scale capital infusion through a mix of equity shares for public investors and convertible warrants for both promoters and public participants.
ஏன் இது முக்கியம்While the fundraise is small relative to the Rs 619 Cr market cap, the participation of a director and promoters in the warrant issuance indicates internal alignment, though it will lead to minor equity dilution.
Equity Issue Value: Rs 9.30 கோடிIssue Price: Rs 250Total Warrants to be Issued: 9,48,000 யூனிட்கள்Fundraise vs Market Cap: ~1.5%Director Allotment (A.K. Sharma): 1,32,000 பங்குகள்
📅 குறுகிய காலம்The stock may see range-bound movement as the issue price (Rs 250) is close to the current market price (Rs 259.9), providing a floor but also signaling limited immediate premium.
📈 நீண்ட காலம்Limited structural impact given the small size of the raise; however, successful conversion of warrants in the future could provide a secondary capital buffer for their 250% capacity expansion plans.
⚠ அபாய எச்சரிக்கைகள்
Minor equity dilution
Related-party participation (Director as allottee)
Specific end-use of funds not detailed in the summary
👀 கவனிக்க வேண்டியவை
Investors should monitor the EGM voting results and the subsequent disclosure regarding the specific end-use of these funds to see if they support the company's ongoing API and Agrochemical capacity expansions.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Rs 33 Cr fundraise via preferential issue of shares and warrants at Rs 250 per share
Shivalik Rasayan's board has approved a total fundraise of Rs 33 crore through a mix of equity shares and convertible warrants. The company will issue 3.72 lakh equity shares to public investors (Rs 9.3 cr) and 9.48 lakh warrants to both promoters and public investors (Rs 23.7 cr). The issue price of Rs 250 represents a ~3.4% premium to the current market price of Rs 241.7. This capital infusion represents approximately 5.7% of the company's current market capitalization.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is initiating a fresh capital raise of Rs 33 crore, involving a mix of immediate equity and deferred equity (warrants) with participation from both promoters and public investors.
ஏன் இது முக்கியம்The fundraise strengthens the company's net worth (currently Rs 405 Cr) and provides liquidity to support its 250% capacity expansion in Agrochemicals and the validation of 20 new APIs for regulated markets.
Total Fundraise Value: Rs 33.00 கோடிIssue Price per Share: Rs 250Fundraise vs Market Cap: ~5.7%Promoter Warrant Subscription: 4,28,000 யூனிட்கள்EGM Date: ஆகஸ்ட் 20, 2026
📅 குறுகிய காலம்The announcement is likely to be viewed positively by the market as the issue price is at a premium to the current market price and includes promoter participation, signaling internal confidence.
📈 நீண்ட காலம்The capital infusion supports the company's structural shift toward high-margin Oncology APIs and expanded Agrochemical capacity, though it results in a ~5.5% equity dilution.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of approximately 5.5% for existing shareholders
Utilization of funds not specifically detailed in the board outcome
👀 கவனிக்க வேண்டியவை
Investors should monitor the EGM outcome on August 20, 2026, and watch for specific disclosures regarding the utilization of these funds, particularly if they are directed toward the Dahej Unit-I API facility or debt reduction.
Shivalik Rasayan FY26 Revenue Up 16% to ₹372 Cr; Net Profit Declines 12%; ₹0.50 Dividend Declared
Shivalik Rasayan reported a 16.2% year-on-year growth in consolidated revenue to ₹372.08 crore for FY26, driven primarily by the Pharma Formulation and API segments. However, consolidated net profit declined by 12% to ₹17.97 crore, impacted by lower margins in the Agrochemicals segment and higher operational expenses. The board has recommended a final dividend of ₹0.50 per share (10% of face value). Additionally, the company saw the resignation of a non-executive director and a change in its internal auditor.
முக்கிய அம்சங்கள்
Consolidated Total Revenue grew 16.2% YoY to ₹37,208.09 Lakhs in FY26.Consolidated Net Profit fell 12% YoY to ₹1,796.88 Lakhs, with EPS dropping to ₹7.71 from ₹10.60.Pharma Formulation segment revenue increased by 21.6% YoY to ₹19,776.97 Lakhs.Agrochemicals segment profit witnessed a decline of 23% YoY to ₹2,202.11 Lakhs.Board recommended a final dividend of ₹0.50 per equity share for the financial year 2025-26.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin pressure in the Agrochemicals business and the progress of the API segment's path to profitability. While revenue growth is healthy, the decline in bottom-line performance and management/auditor changes suggest a 'Watch' approach.
Shivalik Rasayan Q3 Net Profit Drops 47% YoY to ₹3.67 Crore; Revenue Down 4%
Shivalik Rasayan reported a weak set of numbers for Q3 FY26, with consolidated net profit declining significantly by 47% YoY to ₹3.67 crore. Total revenue saw a moderate decline of 4.2% YoY to ₹83.21 crore, primarily dragged down by the Agrochemicals and API segments. The API segment continues to be a drag on profitability, reporting a segment loss of ₹2.57 crore for the quarter. While Pharma Formulations showed slight growth, the overall margin contraction across segments led to a sharp drop in earnings per share from ₹3.39 to ₹1.71.
முக்கிய அம்சங்கள்
Consolidated Net Profit fell 47.1% YoY to ₹3.67 crore from ₹6.94 crore in the previous year's quarter.Total Revenue from operations decreased by 4.2% YoY to ₹83.21 crore compared to ₹86.91 crore.The API segment reported an operating loss of ₹2.57 crore, widening from a loss of ₹1.75 crore YoY.Agrochemicals revenue declined significantly to ₹28.10 crore from ₹37.85 crore in Q3 FY25.Consolidated Basic EPS for the quarter dropped to ₹1.71 from ₹3.39 in the corresponding period last year.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company faces significant margin pressure and persistent losses in its API division. It is advisable to wait for signs of stabilization in the Agrochemicals business and improved profitability in the Pharma segment before considering new positions.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
